# Genetically Modified T Cells Against Ovarian Cancer

> **NCT03184753** · PHASE1,PHASE2 · RECRUITING · sponsor: **Shenzhen Geno-Immune Medical Institute** · enrollment: 100 (estimated)

## Conditions studied

- Ovarian Cancer

## Interventions

- **BIOLOGICAL:** OC-IgT cells

## Key facts

- **NCT ID:** NCT03184753
- **Lead sponsor:** Shenzhen Geno-Immune Medical Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-01
- **Primary completion:** 2028-09-30
- **Final completion:** 2029-12-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03184753

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03184753, "Genetically Modified T Cells Against Ovarian Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03184753. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*